J
28.59
-0.22 (-0.76%)
| Penutupan Terdahulu | 28.81 |
| Buka | 29.29 |
| Jumlah Dagangan | 683,512 |
| Purata Dagangan (3B) | 909,576 |
| Modal Pasaran | 1,719,625,856 |
| Harga / Jualan (P/S) | 100.12 |
| Harga / Buku (P/B) | 1.02 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Operasi (TTM) | -1,216.61% |
| EPS Cair (TTM) | -1.36 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -100.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.23% |
| Nisbah Semasa (MRQ) | 58.47 |
| Aliran Tunai Operasi (OCF TTM) | -46.00 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -27.01 M |
| Pulangan Atas Aset (ROA TTM) | -8.16% |
| Pulangan Atas Ekuiti (ROE TTM) | -9.32% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Janux Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
0.1
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.10 |
|
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 6.69% |
| % Dimiliki oleh Institusi | 113.78% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 150.00 (Cantor Fitzgerald, 424.66%) | Beli |
| Median | 48.00 (67.89%) | |
| Rendah | 32.00 (Clear Street, 11.93%) | Beli |
| Purata | 66.00 (130.85%) | |
| Jumlah | 7 Beli | |
| Harga Purata @ Panggilan | 18.58 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| B of A Securities | 02 Dec 2025 | 49.00 (71.39%) | Beli | 15.86 |
| Cantor Fitzgerald | 02 Dec 2025 | 150.00 (424.66%) | Beli | 15.86 |
| Clear Street | 02 Dec 2025 | 32.00 (11.93%) | Beli | 15.86 |
| HC Wainwright & Co. | 02 Dec 2025 | 45.00 (57.40%) | Beli | 15.86 |
| 25 Nov 2025 | 70.00 (144.84%) | Beli | 34.74 | |
| Stifel | 02 Dec 2025 | 38.00 (32.91%) | Beli | 15.86 |
| 10 Sep 2025 | 45.00 (57.40%) | Beli | 24.31 | |
| Barclays | 07 Nov 2025 | 48.00 (67.89%) | Beli | 26.48 |
| 17 Sep 2025 | 47.00 (64.39%) | Beli | 23.46 | |
| Truist Securities | 10 Sep 2025 | 100.00 (249.77%) | Beli | 24.31 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| MEYER ANDREW HOLLMAN | - | 33.99 | -3,333 | -113,289 |
| Jumlah Keseluruhan Kuantiti Bersih | -3,333 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -113,289 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 33.99 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MEYER ANDREW HOLLMAN | Pegawai | 01 Dec 2025 | Jual automatik (-) | 3,333 | 33.99 | 113,289 |
| MEYER ANDREW HOLLMAN | Pegawai | 01 Dec 2025 | Pelaksanaan pilihan | 3,333 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 01 Dec 2025 | Pengumuman | Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC |
| 24 Nov 2025 | Pengumuman | Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC |
| 06 Nov 2025 | Pengumuman | Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |